ABERA: Positive Q1 2025 result and strong vaccine pipeline progress, supported by grants

About this update from Abera Bioscience Ab

Abera Bioscience reported a positive Q1 2025 net result, driven by grant income and progress in vaccine R&D, with strong preclinical data and regulatory support for clinical trials. Continued funding from CEPI and UK Vaccine Network secures operations. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Abera Bioscience Ab